Observational cohort randomized controlled study to study the influence of correction of ID by intravenous injection of ferric carboxymaltose (Ferinject®) on quality of life indicators, functional status in a cohort of patients with HFpEF.
Signed informed consent to participate in the study;
In New York Heart Association (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF);
Left ventricular ejection fraction (LVEF) ≥50%; objective signs of structural and/or functional disorders of the heart consistent with the presence of LV diastolic dysfunction/increased LV filling pressure, including elevated levels of natriuretic peptide;
Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation (TSAT) is below 20%;
Uncontrolled arterial hypertension;
Аnemia not related to iron deficiency;
Аnemia with a hemoglobin level of less than 90 g/l;
Less than 1 year after acute myocardial infarction;